IGC Pharma, Inc. (IGC): R&D Expense
$3.65M
Year ended 2025-03-31
$4.29M
Trailing 12 months to 2025-09-30
+16.2%
3-year compound annual growth
+29.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-03-31 | $3.65M | -3.1% | 2025-06-27, From 2024-04-01 |
| 2024-03-31 | $3.77M | +9.0% | 2025-06-27, From 2023-04-01 |
| 2023-03-31 | $3.46M | +48.5% | 2024-06-24, From 2022-04-01 |
| 2022-03-31 | $2.33M | +150.8% | 2023-07-07, From 2021-04-01 |
| 2021-03-31 | $929.0K | -8.1% | 2022-06-23, From 2020-04-01 |
| 2020-03-31 | $1.01M | -19.5% | 2021-06-14, From 2019-04-01 |
| 2019-03-31 | $1.26M | +816.8% | 2020-07-13, From 2018-04-01 |
| 2018-03-31 | $137.0K | n/a | 2019-06-14, From 2017-04-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $28.79M | -17.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2024-03-31 | $184.2K | -8.2% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
Compare IGC, VTGN, LGVN, NEUP side by side · Screen every company in Pharmaceutical Preparations ↗